Skip to main content

News

FDA alert
FDA Alert
09/22/2025
Rebecca Mashaw
Guselkumab becomes the first and only interleukin-23 inhibitor to offer both subcutaneous and intravenous induction of therapy for ulcerative colitis and Crohn's disease.
Guselkumab becomes the first and only interleukin-23 inhibitor to offer both subcutaneous and intravenous induction of therapy for ulcerative colitis and Crohn's disease.
Guselkumab becomes the first and...
09/22/2025
Advances in Inflammatory Bowel Disease Network
News
09/18/2025
Jessica Garlewicz
For practicing gastroenterologists, these findings highlight the value of monitoring early changes in albumin during induction therapy.
For practicing gastroenterologists, these findings highlight the value of monitoring early changes in albumin during induction therapy.
For practicing...
09/18/2025
Advances in Inflammatory Bowel Disease Network
News
09/18/2025
Jessica Garlewicz
For gastroenterologists managing treatment-refractory UC, these findings support individualized treatment selection based on prior biologic response.
For gastroenterologists managing treatment-refractory UC, these findings support individualized treatment selection based on prior biologic response.
For gastroenterologists managing...
09/18/2025
Advances in Inflammatory Bowel Disease Network
Research Highlights
09/18/2025
Jessica Garlewicz
Ustekinumab may offer a more durable and effective approach in managing this challenging patient population, new research shows.
Ustekinumab may offer a more durable and effective approach in managing this challenging patient population, new research shows.
Ustekinumab may offer a more...
09/18/2025
Advances in Inflammatory Bowel Disease Network
Research Highlights
09/18/2025
Jessica Garlewicz
New study findings suggest that most baseline concomitant therapies do not require modification or exclusion when initiating advanced therapy in clinical trial settings.
New study findings suggest that most baseline concomitant therapies do not require modification or exclusion when initiating advanced therapy in clinical trial settings.
New study findings suggest that...
09/18/2025
Advances in Inflammatory Bowel Disease Network
Research Highlights
09/15/2025
New analysis of SPARC IBD cohort highlights limited improvement in bowel urgency among patients with Crohn’s disease or ulcerative colitis treated with advanced therapies.
New analysis of SPARC IBD cohort highlights limited improvement in bowel urgency among patients with Crohn’s disease or ulcerative colitis treated with advanced therapies.
New analysis of SPARC IBD cohort...
09/15/2025
Advances in Inflammatory Bowel Disease Network
Research Highlights
09/09/2025
Rebecca Mashaw
Even with minimal inflammation, modifiable psychological and behavioral factors strongly influence fatigue, pain, and fecal incontinence in patients with inflammatory bowel disease.
Even with minimal inflammation, modifiable psychological and behavioral factors strongly influence fatigue, pain, and fecal incontinence in patients with inflammatory bowel disease.
Even with minimal inflammation,...
09/09/2025
Advances in Inflammatory Bowel Disease Network
Research Highlights
09/04/2025
Rebecca Mashaw
New findings show patients with acute severe ulcerative colitis remain at elevated thrombotic risk for up to 12 weeks post-hospitalization.
New findings show patients with acute severe ulcerative colitis remain at elevated thrombotic risk for up to 12 weeks post-hospitalization.
New findings show patients with...
09/04/2025
Advances in Inflammatory Bowel Disease Network
Research Highlights
09/04/2025
Rebecca Mashaw
Patients with fistulizing Crohn’s disease achieved higher rates of fistula resolution and clinical response with upadacitinib versus placebo.
Patients with fistulizing Crohn’s disease achieved higher rates of fistula resolution and clinical response with upadacitinib versus placebo.
Patients with fistulizing...
09/04/2025
Advances in Inflammatory Bowel Disease Network
Research Highlights
09/04/2025
Rebecca Mashaw
Vitamin D supplementation in clinical practice is associated with reduced corticosteroid use and fewer acute care encounters among patients with inflammatory bowel disease.
Vitamin D supplementation in clinical practice is associated with reduced corticosteroid use and fewer acute care encounters among patients with inflammatory bowel disease.
Vitamin D supplementation in...
09/04/2025
Advances in Inflammatory Bowel Disease Network